BriaCell Therapeutics Corp. Warrant expiring 2030 (BCTXZ)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style bargain hunter: I want revenues, earnings, and a margin of safety. BriaCell fails those tests. The business is a development-stage immuno-oncology company with no reported revenue in any filed period. Its lead asset, Bria-IMT for end-stage breast cancer, is in Phase 3, and it also has Bria-OTS and a soluble CD80 program, but hope is not an earnings record. Reported net losses were $20.3M in FY2023, $4.8M in FY2024, and $26.3M in FY2025. In the first three quarters of fiscal 2026, losses continued: $8.2M in Q1, $7.2M in Q2, and $7.2M in Q3. Trailing free cash flow was -$30.0M. FairStock’s metrics underline the stress: Piotroski 1/9, Altman Z-score -5.72, ROE -175.25%, ROCE -90.84%. The warrant traded at $0.19 on 2026-09-04, with a $1.6M market cap. A FairStock P/B of 0.06 looks superficially cheap, but book value in a cash-burning biotech is not a durable moat; it is fuel that can disappear. The competitive moat is unproven—clinical data, patents, and regulatory exclusivity may matter, but the figures show no commercial traction. Growth is not measurable without revenue, and losses plus negative free cash flow mean financing risk and likely dilution. A warrant adds leverage and expiration risk; without the underlying stock exceeding its terms, it can go to zero. For a value investor, this is speculation, not a margin-of-safety bargain.

In plain English: BriaCell is a development-stage cancer-treatment company with no product revenue. It has lost money in each of the last four years, and its cash burn is heavy, so the underlying business looks weak. The $0.19 warrant price is not clearly cheap or expensive versus ordinary business numbers because there are no sales or profits to anchor it; it is a speculative bet on future trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-09-04 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-04-30) · fiscal Q2 2026 10-Q (period ended 2026-01-31) · fiscal Q1 2026 10-Q (period ended 2025-10-31) · fiscal Q3 2025 10-Q (period ended 2025-04-30) · FY2025 10-K (period ended 2025-07-31) · FY2024 10-K (period ended 2024-07-31) · FY2023 10-K (period ended 2023-07-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer